Sight Sciences

OverviewSuggest Edit

Sight Sciences develops ophthalmic device which include glaucoma implants for treatment of irreversible blindness. It provides a portfolio of CE Marked therapy and diagnostic products for vision disorders resulting from a stroke or brain injury.

TypePrivate
Founded2011
HQMenlo Park, US
Websitesightsciences.com

Latest Updates

Employees (est.) (Sept 2020)133(+2%)
Cybersecurity ratingAMore

Key People/Management at Sight Sciences

Paul Badawi

Paul Badawi

Founder & Chief Executive Officer
David Badawi

David Badawi

Founder & Chief Technology Officer
Jesse Selnick

Jesse Selnick

CFO
Shawn O'Neil

Shawn O'Neil

Chief Commercial Officer
Reay H. Brown

Reay H. Brown

Chief Medical Officer
Jeff Francis

Jeff Francis

Vice President of Sales, Surgical Glaucoma
Show more

Sight Sciences Office Locations

Sight Sciences has offices in Menlo Park and Southlake
Menlo Park, US (HQ)
3000 Sand Hill Rd #105
Menlo Park, US
4040 Campbell Ave #100
Southlake, US
2141 E Kirkwood Blvd #130
Show all (3)

Sight Sciences Financials and Metrics

Summary Metrics

Founding Date

2011

Sight Sciences total Funding

$85.5 m

Sight Sciences latest funding size

$30 m

Time since last funding

6 months ago

Sight Sciences investors

Sight Sciences's latest funding round in March 2020 was reported to be $30 m. In total, Sight Sciences has raised $85.5 m
Show all financial metrics

Sight Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Sight Sciences Online and Social Media Presence

Embed Graph

Sight Sciences News and Updates

Sight Sciences Announces First Patients Enrolled in ORION: A Prospective, Multicenter Clinical Trial of the OMNI Surgical System in Pseudophakic, Mild-to-Moderate Glaucoma Patients

MENLO PARK, Calif., Aug. 10, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the enrollment of the first patients in the ORION...

Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

MENLO PARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million in Series D Preferred Stock...

Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

MENLO PARK, Calif., Oct. 23, 2018 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has joined the company as Chief...

Sight Sciences Blogs

First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled in OLYMPIA, the U.S. pivotal trial to further assess the safety and efficacy of TearCare…

Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

  New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows   MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and g…

First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™ Surgical System in performing two sequential Micro-Invasive Glaucoma Surgery (MIGS) proc…

Clinical Study Demonstrates Long Term IOP Reduction With The OMNI® Surgical System Predicate Device (TRAB®360) In Micro-Invasive Glaucoma Surgery

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s Predicate Devices (TRAB®360) provides a favorable safety profile and substantia…

American Glaucoma Society (AGS)

March 14-17 San Francisco, CA Contact Sight Sciences today to schedule a meeting. The post American Glaucoma Society (AGS) appeared first on Sight Sciences.

Vision Expo East

March 21-24 New York, NY Contact Sight Sciences today to schedule a meeting. The post Vision Expo East appeared first on Sight Sciences.
Show more

Sight Sciences Frequently Asked Questions

  • When was Sight Sciences founded?

    Sight Sciences was founded in 2011.

  • Who are Sight Sciences key executives?

    Sight Sciences's key executives are Paul Badawi, David Badawi and Jesse Selnick.

  • How many employees does Sight Sciences have?

    Sight Sciences has 133 employees.

  • Who are Sight Sciences competitors?

    Competitors of Sight Sciences include Biovotion, GoHealth Urgent Care and Bio-AMD.

  • Where is Sight Sciences headquarters?

    Sight Sciences headquarters is located at 3000 Sand Hill Rd #105, Menlo Park.

  • Where are Sight Sciences offices?

    Sight Sciences has offices in Menlo Park and Southlake.

  • How many offices does Sight Sciences have?

    Sight Sciences has 3 offices.